Clinical Trials Related to Rare Disease

Related studies linked through entity extraction aliases.

Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients

Status: RECRUITING
Phase: N/A

Longitudinal Registry Including Patients Treated With Heavy Particles

Status: RECRUITING
Phase: N/A

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Status: TERMINATED
Phase: PHASE2

Idiopathic Diseases of Man

Status: ENROLLING_BY_INVITATION
Phase: N/A